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Abstract
Objective In recent years, gamma knife radiosurgery (GKRS) has become increasingly more popular as a salvage treat-
ment modality for patients diagnosed with recurrent gliomas. The goal of GKRS for recurrent glioma patients is to improve 
survival rates with minimal burden for these patients. The emphasis of this report is on local tumor control (TC), clinical 
outcome and survival analysis.
Methods We performed a retrospective analysis of prospectively collected data of all patients who underwent GKRS for 
gliomas at the Gamma Knife Center Tilburg between 23-09-2002 and 21-05-2015. In total, 94 patients with glioma were 
treated with GKRS. Two patients were excluded because GKRS was used as a first stage treatment. The other 92 patients 
were included for analysis.
Results TC was 37% for all tumors (TC was 50% in LGGs and 27% in HGGs). Local progression (LP) was 46% for all tumors 
(LP was 31% in LGGs and 58% in HGGs). New distant lesions were seen in 18% of all patients (in 5% of LGG patients and 
31% of HGG patients). Median progression-free and overall survival (PFS and OS) for all patients were 10.5 and 34.4 months, 
respectively. Median PFS was 50.1 and 5.7 months for low and high grade tumors, respectively. Median OS was 86.6 and 
12.8 months for low and high grade tumors, respectively. No serious adverse events were noted post-GKRS.
Conclusion GKRS can safely be used as salvage treatment for recurrent glioma and seems to improve survival rates in (high 
grade) glioma patients with minimal burden.
Keywords Gamma knife radiosurgery · Recurrent · Gliomas
Introduction
Gliomas are the most common primary malignant brain 
tumors. The overall age-adjusted incidence rates for all 
gliomas range between 4.67–5.73/100,000 persons/year [1, 
2]. Gliomas have been classified into four grades of ascend-
ing malignancy by the World Health Organization (WHO). 
Essentially, they can be divided into two major groups: 
low grade gliomas (LGG; WHO 1–2) and high grade glio-
mas (HGG; WHO 3–4). GBM (WHO grade 4) is the most 
deadly glioma in adults with an overall 5 year survival of 
0.05–4.7% [3–7]. Generally, gliomas are more common in 
men than in women [3, 8–10]. Currently, the treatment of 
gliomas consists of maximal safe surgical resection, external 
beam radiation therapy (EBRT), and chemotherapy. How-
ever, these tumors do often reoccur. Options for salvage 
treatment are repeated surgery, re-irradiation with EBRT, 
chemotherapy, novel therapies, or a combination of these 
treatments. Repeated surgery can be a good option as a sal-
vage treatment, but might be associated with postoperative 
complications. Treatment with EBRT for a second time can 
be accompanied by high risk of radiation-related toxicity and 
necrosis. In recent years, gamma knife radiosurgery (GKRS) 
has become increasingly more popular as a salvage treatment 
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modality for patients diagnosed with recurrent gliomas. The 
goal of GKRS for recurrent glioma patients is to improve 
survival rates with minimal burden for these patients. We 
summarize our experience in a group of 92 patients with 
recurrent glioma, treated with GKRS. The emphasis of this 
report is on local tumor control (TC), clinical outcome and 
survival analysis.
Methods
Case selection
We performed a retrospective analysis of prospectively col-
lected data of all patients who underwent GKRS for gliomas 
at the Gamma Knife Center Tilburg between 23-09-2002 
and 21-05-2015. The study was approved by the medical 
ethical committee. Hospital records, including clinical notes, 
doctors’ letters, radiology reports and demographic data, 
were reviewed and relevant information was extracted for 
analysis. Pre- and post-GKRS clinical characteristics were 
reviewed. We included all patients with histologically con-
firmed gliomas. In total, 94 patients with glioma were treated 
with GKRS. Two patients were excluded because GKRS was 
used as a first stage treatment. The other 92 patients were 
included for analysis.
Baseline characteristics
As stated, 92 patients (52 males and 40 females) underwent 
GKRS for recurrent glioma. The median age at time of 
GKRS was 50 years (range 7–76) (Table 1). The histopa-
thology of the tumors is summarized in Table 2. Eighty-five 
patients had undergone at least one operation before GKRS. 
Seven patients received biopsy followed by adjuvant treat-
ment in the form of chemotherapy, EBRT or a combination 
of both, before GKRS. Pre-GKRS treatment features are 
summarized in Table 1.
Gamma knife radiosurgical procedure
The GKRS procedure was performed using the Leksell 
Gamma Knife 4C, before 2009, and Leksell Gamma Knife 
Perfexion thereafter. GammaPlan Software (Elektra) was 
used for treatment planning. The application of the Lek-
sell G-Frame with fixation posts and screws at four points 
was performed at the patients room using a local anaesthetic 
solution (9 ml of lidocaine 2% + epinephrine 0.125% com-
bined with 1 ml of  NaHCO3 84 g/1000 ml). Following frame 
placement, high resolution stereotactic MRI was performed 
for treatment planning. Pre- and post-contrast (Triple dose 
Gadolinium) T1 weighted axial images were obtained with 
a slice thickness of 1.5 mm. Stereotactic radiosurgery and 
dose planning were then performed in consultation with a 
neurosurgeon, radiation-oncologist, and medical physicist. 
The target was defined as the contrast enhancing lesion on 
the planning MRI-scan. Target delineation was limited to the 
target enhancing lesion only for progressive LGG (WHO I 
and II) and HGG (WHO III and WHO IV) as confirmed by 
the ASTRO guidelines [11]. The median number of lesions 
treated with GKRS was 1 (range: 1–4) with a median tumor 
volume of 2.22 cm3 (range: 0.01–9.95). Eventually, a total 
of 107 (48 LGG and 59 HGG) tumors were treated with 
GKRS. The prescribed dose (PD) ranged between 12 and 
25 Gy (median 18 Gy) to that isodose covering 89–100% of 
the target (Table 1).
Table 1  Pre-GKRS patient characteristics and radiosurgical features
EBRT External beam radiotherapy, PD Prescribed dose, PVC Procar-
bazine, Lomustine and vincristine, TMZ Temozolomide
Patient characteristics No. of patients (%)
Total patients included 92
Male: female ratio 52:40
Median age (range) 50 (7–76)
Median Karnofski index (range) 90 (50–100)
 ≥ 70 80
 < 70 12
Histopathology
 WHO I glioma 17 (19%)
 WHO II glioma 26 (28%)
 WHO III glioma 24 (26%)
 WHO IV glioma 25 (27%)
Primary surgery
 Complete resection 78 (84%)
 Subtotal resection 7 (8%)
 Biopsy 7 (8%)
Adjuvant therapy
 Repeated surgery 1 (1%)
 PVC + EBRT + adjuvant TMZ 26 (28%)
 EBRT + TMZ 2 (2%)
 EBRT only 40 (43%)
Target location
 Infratentorial 19 (18%)
 Supratentorial 88 (82%)
Unifocal 79 (86%)
Multifocal 13 (14%)
Median tumor volume in  cm3 (range) 2.22 (0.01–9.95)
Radiosurgical features
 Median PD in Gy (range) 18 (12–25)
 Median minimal dose in Gy (range) 17.7 (9.4–26.1)
 Median maximal dose in Gy (range) 34.6 (19.4–51.2)
 Median isodose in % (range) 52 (39–93)
 Median coverage in % (range) 99 (89–100)
 Median no. of lesions treated (range) 1 (1–4)
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The median PD for LGG and HGG was 18 Gy ranging 
between 12 and 25 Gy and 14–25 Gy, respectively. After 
GKRS, patients received 8 mg dexamethasone for 5 days and 
thereafter the dose was decreased to 0 mg within 1 week.
Radiological classification for progression
Determining radiological progression (after treatment) is a 
difficult task for gliomas, especially differentiating between 
progression/recurrence and treatment induced radiological 
changes. Therefore, we have introduced the Tilburg radio-
logical classification for scoring TC after GKRS. Figure 1 
shows the Tilburg classification on which we based our 
definitions of tumor progression. A subdivision was made 
between local TC with or without (a) new distant lesion(s).
Statistical analysis
Data are represented as median with the range. The Pearson 
correlation coefficient was obtained through linear regres-
sion analysis. Survival analysis was done by log rank test 
on Kaplan Meier survival estimates. Survival was defined 
as time from GKRS till death or last FU. Statistics were 
calculated with Prism software 7 (GraphPad Software Inc., 
San Diego, CA, USA).
Results
Radiosurgical response/radiological tumor control
TC was achieved in 37% of all tumors treated. According to 
tumor grade, TC was obtained in 50% of LGGs (24 out of 48 
tumors) and in 27% of HGGs (16 out of 59 tumors). Local 
progression (LP) occurred in 46% of all tumors, in 31% of 
LGGs (15 out of 48 tumors) and in 58% of HGGs (34 out 
of 59 tumors). Marginal progression occurred in 9% of all 
tumors, in 6% of LGGs (3 out of 48 tumors) and in 12% 
of HGGs (7 out of 59 tumors). New distant lesions (NDL) 
were seen in 18% of all patients; in 5% of LGG patients (2 
out of 43 patients) and 31% of HGG patients (15 out of 49 
patients) (Table 2). One (LGG) patient had leptomeningeal 
disease (Table 2).
Survival and prognostic factors/clinical outcome
Kaplan Meier survival curves are given in Fig.  2. 
Median progression-free and overall survival (PFS 
and OS) for all patients were 10.5 and 34.4  months, 
respectively (Fig. 2). Median PFS was not yet reached 
for grade 1 (range 7.7–139.4 months), 14.3 months for 
grade 2 (range 2.8–139.1 months), 8.8 months for grade 
3 (range 1.5–49.6 months) and 4.4 months for grade 4 
glioma (range 0.4–18.1  months). Median OS for the 
Table 2  Histopathology 
and radiosurgical response 
according to the Tilburg 
radiological classification
Lepto Leptomeningeal, LP Local progression, MP Marginal progression, NDL New distant lesion, TC 
Tumor control
Histopathology No. of patients No. of tumors TC LP MP NDL
WHO I
 Pilocytic astrocytoma 10 10 7 3
 Subependymoma 4 4 2 1 1
 Myxopapillary ependymoma 1 2 2
 Ganglioglioma 1 1 1
 Subependymal giant cell astrocytoma 1 1 1
WHO II
 Oligodendroglioma 11 12 3 9 5
 Ependymoma 10 13 11 1 7 + 1 Lepto
 Astrocytoma 2 2 1 1
 Oligoastrocytoma 2 2 1 1 1
 Central neurocytoma 1 1 1 1
WHO III
 Anaplastic oligodendroglioma 11 15 4 6 3 5
 Anaplastic astrocytoma 7 10 4 3 2 4
 Anaplastic ependymoma 3 3 1 2
 Anaplastic oligoastrocytoma 3 3 2 1 1
WHO IV
 Glioblastoma multiforme 25 28 7 21 1 5
Total 92 107
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aforementioned tumor grades was not yet reached (range 
7.7–139.4 months), 47.2 months (range 2.8–139.1 months), 
18.1 months (range 3.3–52.0 months) and 10.4 months 
(range 1.4–32.7 months), respectively. There was a highly 
significant increase in both PFS and OS according to tumor 
grade; i.e. the lower the tumor grade, the better the out-
come (Fig. 2). Low grade tumors were defined as grade 1 
and 2 tumors, high grade tumors as grade 3 and 4 tumors. 
Median PFS was 50.1 months (range 1.3–139.4 months) 
and 5.7 months (range 0.4–92.5 months) for low and high 
grade tumors, respectively. Median OS was 86.6 months 
(range 1.3–139.4  months) and 12.8  months (range 
0.5–109.5 months) for low and high grade tumors, respec-
tively (Fig. 2). There was no correlation between time 
from first diagnosis to GKRS and PFS. The median follow-
up (FU) was 34 months from the date of GKRS treatment. 
We lost 56 patients during FU. All of these patients died 
due to intracranial progressive disease.
Adverse events
Seventy-nine percent (36 out of 48) of the LGG patients 
had no adverse events. Frame related swelling occurred in 
10% (5 out of 48) of the patients within a median time of 
14 days (Table 3).
In HGG patients, 59% had no adverse events. In this 
group the incidence of frame related swelling was compa-
rable to that of LGG patients. Other adverse events for both 
LGG and HGG patients are summarized in Table 3. No 
serious adverse events were noted after GKRS (Table 3).
Fig. 1  Tilburg radiological classification
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Fig. 2  Progression-free and overall survival (PFS and OS) for all 
patients and according to tumor grade (LGG vs. HGG). Median 
PFS was 10.5 months (range 0.4–139.4 months) and median OS was 
34.4  months (range 0.5–139.4  months). (mo months). Low grade 
tumors were defined as grade 1 and 2 tumors, high grade tumors 
as grade 3 and 4 tumors. Median PFS was 50.1 months (range 1.3–
139.4 months) and 5.7 months (range 0.4–92.5 months) for low and 
high grade tumors respectively. Median OS was 86.6 months (range 
1.3–139.4  months) and 12.8  months (range 0.5–109.5  months) for 
low and high grade tumors respectively. (mo months, vs versus)
Table 3  Adverse events after 
radiosurgery
a CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events)
Adverse  eventsa LGG Median time to occur HGG Median 
time to 
occur
None 36 (79%) 35 (59%)
Frame related swelling/pain 5 (10%) 14 days 5 (9%) 28 days
Headache (grade 1) 0 3 (5%) 28 days
Headache (grade 2) 2 (4%) 84 days 1 (2%) 28 days
Sensitive headskin (grade 1) 1 (2%) 14 days 1 (2%) 56 days
Focal alopecia (grade 1) 1 (2%) 21 days 0
Concentration loss (grade 1) 1 (2%) 56 days 0
Fatigue (grade 1) 1 (2%) 9 days 3 (5%) 28 days
Dizziness (grade 1) 1 (2%) 56 days 0
Vertical diplopia (grade 1) 1 (2%) 6 months 0
Somnolence (grade 1) 1 (2%) 18 days 0
Focal epilepsy (grade 1) 1 (2%) 20 days 3 (5%) 1 day
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Discussion
In recent years, GKRS has become increasingly more pop-
ular as a salvage treatment modality for patients diagnosed 
with recurrent gliomas. The goal of GKRS for recurrent 
glioma patients is to improve survival rates with minimal 
burden for these patients. One can argue about what type 
of treatment is best for patients with recurrent glioma. 
This is dependent on several factors, such as patient’s age, 
comorbidity, Karnofski-Index, histopathological diagnosis 
and available treatment modalities. In our center, a differ-
ence is made between low grade and high grade tumors. 
Patients with recurrent low grade tumors are more suit-
able to undergo reoperation because these tumors are less 
responsive to radiosurgery. However, this is dependent on 
location and tumor volume. Patients with recurrence in 
eloquent locations and/or with small tumor volume are 
less suitable to undergo reoperation and are more suitable 
candidates to undergo minimal invasive treatment such 
as GKRS. In case of high grade tumors, patients with 
recurrence have limited survival [12–14] and are more 
eligible for GKRS. Moreover, high grade tumors have a 
better radio-surgical response in comparison to low grade 
tumors. Finally, for patients with glioma the quality of life 
(QoL) is an increasingly important recognized factor. Not 
only do these patients suffer from general symptoms asso-
ciated with cancer, such as fatigue, anxiety, and depres-
sion, but also from seizures, cognitive deficits, and focal 
neurological deficits. Therefore, treatments leading to 
deterioration of QoL are less favorable for these patients, 
giving their short lifespan, making GKRS an excellent 
treatment modality for maintaining QoL and extending 
survival time.
Determining radiological progression is known to be 
difficult for gliomas, especially after different treatment 
modalities have been applied. Until recently, clear defini-
tions of progression and pseudo-progression have been 
lacking, which makes comparison between different stud-
ies on treating recurrent glioma bothersome. For this, the 
RANO (Response Assessment in Neuro-Oncology) crite-
ria have been proposed to score radiological (pseudo-) pro-
gression more uniformally. However, these RANO criteria 
have not specifically been designed for patients treated 
with GKRS. Therefore, we have introduced the Tilburg 
radiological classification for scoring TC after GKRS. The 
primary goal of this classification is to allow us to com-
pare our own treatment results more objectively. Further-
more, this classification could form the basis for uniform 
radiological criteria scoring radio-surgical response.
In our study, TC was achieved in 37% of all tumors; 
50% in LGGs and 27% in HGGs. A recent study showed a 
53.8% TC for LGGs after GKRS [15], which is comparable 
to our study. For HGGs, the TC is within range of other 
studies which reported TC of 18.8%–75.6% [16–19]. LP 
occurred in 46% of all tumors treated with GKRS. This 
might indicate a dose problem, meaning that a higher dose 
is needed to obtain a higher local TC. Another important 
subject is target definition which led to marginal progres-
sion in 9% of all tumors in our study. Koga et al. were 
the first to address these two problems [19]. They com-
pared two groups, conventional SRS (20 Gy applied to 
the margin of each gadolinium-enhanced lesion) versus 
extended field SRS (margin was extended up to 0.5–1 cm). 
TC in the conventional group was 47%. By extending the 
margin of the clinical target volume the TC increased to 
93% (P = 0.0035). However, there was no significant dif-
ference (P = 0.83) in survival time between the two groups. 
A higher incidence of radiation necrosis was seen in the 
extended SRS group (29% vs. 6.5%). The goal of extend-
ing the irradiation field is to include as many tumor cells 
invading the surrounding tissue as possible. A limitation 
of this method is that it is not applicable to large lesions. 
Extending the margin in a large target results in a large 
prescribed isodose volume and might cause uncontrolla-
ble radiation induced adverse events. In case of GKRS 
as salvage treatment, the goal is prolonged survival with 
minimal burden. Therefore we do not find it useful to irra-
diate more than the enhanced lesion because of the higher 
incidence of radiation necrosis and uncontrolled radia-
tion induced adverse events. Gliomas are highly vascular 
tumors and have a tendency to infiltrate extensive areas 
of the brain. The real tumor may therefore be much larger 
than what is seen on MRI, making a 0.5–1 cm margin still 
insufficient. This is another reason to only irradiate the 
enhanced lesion for both high and low grade gliomas.
The median PFS and OS for all patients were 10.5 and 
34.4 months, respectively. Median PFS was 50.1 months 
and 5.7 months for low and high grade tumors respectively. 
Median OS was 86.6 months and 12.8 months for low and 
high grade tumors respectively. This is comparable to other 
studies about GKRS for recurrent HGG who showed a 
median OS ranging from 13 to 14 months [18, 20–22].
Other studies in which radiosurgery was performed using 
a linear accelerator (LINAC) for the treatment of recurrent 
HGG showed comparable median OS ranging from 8.5 
to 11 months [23–25]. As could be expected, there was a 
highly significant increase in both PFS and OS according to 
tumor grade (i.e. the lower the tumor grade, the better the 
outcome), reflecting the natural behaviour of these tumors 
and sensitivity to treatment. Of clinical interest, in recurrent 
GBM patients median OS was 10.4 months. This shows that 
GKRS can meaningfully lengthen survival in these patients 
with a 1  day hospitalization, maintenance of QoL and 
minimal burden. For patients with a limited life span, these 
advantages should make one consider GKRS as a treatment 
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option in recurrent glioma patients, as opposed to systemic 
treatment modalities that might hamper QoL (and might 
increase the number of hospital visits needed for therapy).
It is important to note that there were no serious adverse 
events and that the therapy was well tolerated. In general, 
only mild adverse events were noticed and GKRS was well 
tolerated.
In the Netherlands, the first line of therapy for HGG is 
surgical resection followed by chemo-radiation [26]. In case 
of recurrence, several options do exist: repeat surgery, RT, 
chemotherapy, experimental therapy or a combination of 
these treatment modalities, all depending on the clinical 
state of the patient. We are one of only two centers in the 
Netherlands who have access to GKRS. In case of recur-
rent glioma we can use high single dose radiation for small 
(multiple) lesions without causing damage to surrounding 
brain tissue, which already has been exposed to radiation. 
This is a clear advantage over conventional RT. Therefore, 
our recommendation is to use GKRS if possible in small 
recurrent glioma since one can give a higher dose radiation 
in an already irradiated brain compared to conventional RT, 
minimizing the possible risk of side-effects.
We use triple dose gadolinium for the planning MRI-scan 
in combination with a small slice thickness of 1.5 mm. This 
allows for detection of very small recurrence lesions. This 
is another advantage of using GKRS, because we can treat 
lesions in a very early stage of recurrence.
Limitations of the study
This is a single-center retrospective study with a relatively 
small number of patients and therefore subjected to biases 
(selection bias and treatment bias) and limitations. The 
recurrent glioma volume that was treated was rather small, 
as a result of selection bias. The patients that are eligible 
for GKRS treatment, are patients with smaller tumor vol-
umes. As a result, the patients that are treated with GKRS 
probably have a less unfavourable prognosis. All patients 
were pre-treated before GKRS. Major limitations are non-
protocolized treatment regiments. The treatment included 
multiple surgeries, use of chemotherapeutic agents, different 
radiotherapy regimens, and heterogeneity in primary brain 
tumors. Therefore the group we present is very heteroge-
neous, which makes comparison to historical groups very 
difficult.
Conclusion
GKRS can safely be used as salvage treatment for recurrent 
glioma and seems to improve survival rates in (high grade) 
glioma patients with minimal burden.
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